ABOUT EVENT
So What’s New for 2024?
Alessio Ciulli & Stuart Schreiber join the speaker faculty!
Presenting their latest work on molecular glues and intramolecular bivalent glues, these legends of the TPD field will take to the stage on the very first day of the summit (October 28th) within our brand new, New Frontiers in TPD & Induced Proximity Research Day, featuring exclusively Key Opinion Leading academics
Kicking off our first industry-focused day (October 29th), the Chief Executive Officers from the field’s leading biotechs will share their personal thoughts on the current state-of-play, in a series of specially sessions designed to glean precious insights from the minds of the foremost thinkers.
- Nello Mainolfi, Chief Executive Officer, Kymera Therapeutics
- Andrew Hirsch, President & Chief Executive Officer, C4 Therapeutics
- Arthur Sands, Chief Executive Officer, Nurix Therapeutics
- Adrian Gottschalk, Chief Executive Officer, Foghorn Therapeutics
CEO Think Tank
New Clinical Data
On October 30th we welcome to our Keynote, Plenary session, Nurix Therapeutics & Foghorn Therapeutics presenting clinical updates on a degrader asset in clinic. You will not want to miss this!
- The field of dealmaking and collaboration in TPD has shown no signs of slowing over the past 6 months, with Merck US & KgGA, C4 Therapeutics, Novo Nordisk, Monte Rosa, Nurix, Seagen, Neomorph, Bristol Myers Squibb, Orum, Novartis and so many more striking multi million $ deals to secure future development of degraders in 2025 and beyond.
- Finding the right partnership and creating a working relationship that fits has never been more crucial to ensuring novel work can continue flourishing in the protein degradation ecosystem.
- This is why we’re introducing for the first time, a dedicated session exploring trends in platform and assets deals across the TPD space uniting the very people involved in those deals
- Scott Boyle, Chief Business Officer, C4 Therapeutics
- Randy Teel, Chief Business Officer, Arvinas
- Mark Stencik, Head Associate VP, Transactions,
Merck & Co.
Trends in Partnerships & Investments in TPD
The 7th TPD & Induced Proximity Summitis the world’s singular most important forum for uniting leaders in industry and academia from all 4 corners of the globe to not only showcase success stories, but also critically, to raise challenges to the forefront of conversation and overcome them, together.
Spanning 4-days, our summit will unearth new findings and learnings across the entire end-to-end spectrum of TPD & Induced Proximity drug development:
OCTOBER 28 2024
Interested in structure-based drug design? Deep-dive into structure-based discovery and novel SAR approaches in a dedicated workshop on
- New to TPD? Attend our TPD 101 Bootcamp Day to learn the basics of TPD and fundamental principles underpinning induced proximity, PROTACs, and molecular glue functionality and application.
- Running assays and screening your compound against massive libraries? We have merged our TPD Assay Development & Screening Summit into a content-packed focus day as part of our flagship meeting with the like of BMS, Novartis, A-Alpha Bio, and many more showcasing their assay innovations.
OCTOBER 29-30 2024
Split into 3 tracks this year, the 7th TPD & Induced Proximity Summit promises to bring first class insight and new data across every stage of the drug development timeline. Hear from newcomers TenAces Bio on their approach to rational molecular glue discovery, discover novel PK/PD models that are informing in vivo to in vitro with Bayer AG, and uncover how leading orally bioavailable drug candidates are performing in clinic with Prelude Therapeutics.
Introducing a brand new Award this year, the Annual TPD Awards return on the evening of the 29th October for an unmissable celebration of the outstanding work done across the year to propel the degrader and induced proximity field forward.
OCTOBER 31 2024
Wrap up the summit with a look to the future, with a collection of the field’s forward thinkers pushing the boundaries of what the technologies, and current understanding of protein degradation, PROTAC machinery, and monovalent degraders can achieve. Dive into phosphorylation with PHOSTACs, extracellular degradation with ATACs, the interface between the mRNA space and TPD with BioPROTACs, non-degrading techniques with RIPTACs, and cell membrane interactions with SureTACs.
Brand New Companies!
Divide and Conquer:
The field of TPD & Induced Proximity is vast, which is why we have meticulously researched with subject matter experts to identify the key challenges facing the community, from senior scientists, to directors, to C-Level executives… the problems are different, but together we can tackle them.
By splitting into 3 tracks; Discovery, Preclinical, and Clinical our speakers can tailor their presentations to hone on specific challenges for those stages of development. By sending different members of the team across the drug pipeline, you can be sure you’ve left no stone unturned.
A Snapshot of the morning sessions in each track:
DISCOVERY
PRECLINICAL
CLINICAL
Integrating AI technology with Physics-Based Approach to Consider Thermodynamic Cycles of Ternary complex Formation for Molecular Glue Discovery
Keunsoo Kang, Chief Scientific Officer, Deargen
Rational Design of Selective MGDs
Magnus Walter, Senior Vice President Drug Discovery, Monte Rosa Therapeutics
An Orally Bioavailable, Oncogenic Mutant-Selective Degrader with CNS Exposure & Activity for the Treatment of Naive & Treatment-Resistant Solid Tumors
Ya-Wen Lu, Associate Director Cell Biology, Nurix Therapeutics
Developing Optimized Folding Interfering Degraders Targeting Cyclin D1
Giovanni Spagnolli, Chief Technology Officer, Sibylla
Clinical Insights on Leveraging Kinetics-Based PKPD Modelling to Drive Degrader Optimization
Stewart Fisher, Chief Scientific Officer, C4 Therapeutics
Ultra-High-Throughput Miniaturized Cell-Based Assays to Discover Molecular Glue Degraders of IKZF2 & CDK2
JF Brazeau, Director, Plexium